STRATA Skin Sciences Announces Regulatory Approval of XTRAC Momentum 1.0 Device in Japan
HORSHAM, Penn. July 22, 2024 STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a leader in medical technology focused on the development, commercialization, and marketing of innovative dermatologic treatments, has announced the official approval of its XTRAC Momentum 1.0 device by Japan’s Ministry of Health, Labor and Welfare. The regulatory green light will allow STRATA to implement an immediate commercial rollout in partnership with JMEC Co. Ltd. its longstanding strategic partner and distributor in Japan.
The XTRAC Momentum 1.0 device initially made its debut in the U.S. market in early 2022. Its introduction to the Japanese market aims to fortify STRATA’s presence in a country where its excimer laser devices are already trusted by over 300 hospitals and private dermatology clinics. STRATA’s innovations in excimer technology are utilized for the non-invasive treatment of various dermatologic conditions, promising to further elevate the standard of care within the sector.
Dr. Dolev Rafaeli, CEO of STRATA Skin Sciences, emphasized the strategic importance of the approval, stating, “The authorization of the XTRAC Momentum 1.0 device in Japan marks a significant milestone for STRATA. It not only aligns with our mission to broaden the global reach of our advanced dermatological solutions but also facilitates improved patient outcomes through state-of-the-art technology.”
The alliance with JMEC Co. Ltd. offers considerable momentum, leveraging the distributor’s extensive logistical acumen and network within the Japanese healthcare system to ensure a seamless introduction of the device into clinical settings. JMEC’s established rapport and capability to disseminate medical innovations are expected to reinforce STRATA’s market penetration and operational efficiency in Japan.
The launch of XTRAC Momentum 1.0 in Japan reflects our commitment to expanding access to cutting-edge therapeutic solutions on a global scale,” said JMEC’s spokesperson. “We are excited to bring this innovative technology to our healthcare professionals and patients, advancing the treatment paradigm for dermatologic conditions.
With regulatory approval secured, STRATA Skin Sciences is poised to make substantial inroads into the Asian market, amplifying the accessibility and applicability of its pioneering dermatologic treatments. As the healthcare community continues to seek effective and non-invasive therapeutic alternatives, the XTRAC Momentum 1.0 device stands to set a new benchmark in dermatologic care.
For more details on STRATA’s array of dermatology-focused technologies and initiatives, visit the company’s official website or follow their latest updates through their social media channels.
Comments